Medicure Inc. (MPH.V)
CAD 0.83
(0.0%)
CAD 0.83
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.16 Million CAD | -8.21% |
| 2022 | 8.89 Million CAD | -11.04% |
| 2021 | 9.99 Million CAD | -32.94% |
| 2020 | 14.9 Million CAD | -2.83% |
| 2019 | 15.34 Million CAD | -23.93% |
| 2018 | 20.16 Million CAD | -58.18% |
| 2017 | 48.22 Million CAD | -72.56% |
| 2016 | 175.76 Million CAD | 946.52% |
| 2015 | 16.79 Million CAD | 60.39% |
| 2014 | 10.47 Million CAD | 0.0% |
| 2012 | 7.75 Million CAD | 18.07% |
| 2011 | 6.56 Million CAD | -79.53% |
| 2010 | 32.06 Million CAD | 3.68% |
| 2009 | 30.92 Million CAD | 6.3% |
| 2008 | 29.09 Million CAD | -29.65% |
| 2007 | 41.36 Million CAD | 62.33% |
| 2006 | 25.47 Million CAD | 1449.52% |
| 2005 | 1.64 Million CAD | -39.83% |
| 2004 | 2.73 Million CAD | 234.25% |
| 2003 | 817.57 Thousand CAD | 131.01% |
| 2002 | 353.9 Thousand CAD | -9.18% |
| 2001 | 389.66 Thousand CAD | -31.65% |
| 2000 | 570.07 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 8.16 Million CAD | 0.07% |
| 2024 Q2 | 8.69 Million CAD | 6.44% |
| 2023 Q4 | 8.16 Million CAD | 16.97% |
| 2023 Q2 | 7.96 Million CAD | -0.81% |
| 2023 FY | 8.16 Million CAD | -8.21% |
| 2023 Q3 | 6.97 Million CAD | -12.35% |
| 2023 Q1 | 8.02 Million CAD | -9.74% |
| 2022 Q3 | 9 Million CAD | -20.51% |
| 2022 Q4 | 8.89 Million CAD | -1.2% |
| 2022 FY | 8.89 Million CAD | -11.04% |
| 2022 Q1 | 9.48 Million CAD | -5.15% |
| 2022 Q2 | 11.32 Million CAD | 19.43% |
| 2021 Q3 | 13.12 Million CAD | -4.22% |
| 2021 Q1 | 13.92 Million CAD | -6.59% |
| 2021 Q4 | 9.99 Million CAD | -23.84% |
| 2021 FY | 9.99 Million CAD | -32.94% |
| 2021 Q2 | 13.7 Million CAD | -1.58% |
| 2020 Q2 | 11.38 Million CAD | -30.65% |
| 2020 FY | 14.9 Million CAD | -2.83% |
| 2020 Q3 | 10.14 Million CAD | -10.86% |
| 2020 Q1 | 16.41 Million CAD | 7.01% |
| 2020 Q4 | 14.9 Million CAD | 46.89% |
| 2019 FY | 15.34 Million CAD | -23.93% |
| 2019 Q2 | 16.89 Million CAD | -9.46% |
| 2019 Q3 | 18.09 Million CAD | 7.11% |
| 2019 Q1 | 18.65 Million CAD | -7.48% |
| 2019 Q4 | 15.34 Million CAD | -15.21% |
| 2018 Q1 | 15.21 Million CAD | -68.45% |
| 2018 FY | 20.16 Million CAD | -58.18% |
| 2018 Q4 | 20.16 Million CAD | 6.95% |
| 2018 Q3 | 18.85 Million CAD | -10.39% |
| 2018 Q2 | 21.04 Million CAD | 38.29% |
| 2017 FY | 48.22 Million CAD | -72.56% |
| 2017 Q4 | 48.22 Million CAD | -69.01% |
| 2017 Q3 | 155.61 Million CAD | 0.44% |
| 2017 Q2 | 154.93 Million CAD | -0.69% |
| 2017 Q1 | 156 Million CAD | -11.24% |
| 2016 FY | 175.76 Million CAD | 946.52% |
| 2016 Q2 | 12.63 Million CAD | -2.19% |
| 2016 Q1 | 12.91 Million CAD | -23.1% |
| 2016 Q3 | 11.26 Million CAD | -10.86% |
| 2016 Q4 | 175.76 Million CAD | 1460.93% |
| 2015 Q4 | 16.79 Million CAD | 64.86% |
| 2015 Q1 | 10.29 Million CAD | 0.0% |
| 2015 Q3 | 10.18 Million CAD | -0.48% |
| 2015 FY | 16.79 Million CAD | 60.39% |
| 2015 Q2 | 10.23 Million CAD | -0.54% |
| 2014 FY | 10.47 Million CAD | 0.0% |
| 2014 Q1 | 9.15 Million CAD | 7.36% |
| 2014 Q2 | 9.48 Million CAD | 3.58% |
| 2014 Q3 | 9.92 Million CAD | 4.66% |
| 2013 Q1 | 7.33 Million CAD | 10.9% |
| 2013 Q2 | 7.75 Million CAD | 5.67% |
| 2013 Q3 | 8.07 Million CAD | 4.24% |
| 2013 Q4 | 8.52 Million CAD | 5.57% |
| 2012 Q2 | 6.56 Million CAD | 0.47% |
| 2012 FY | 7.75 Million CAD | 18.07% |
| 2012 Q4 | 6.61 Million CAD | 3.7% |
| 2012 Q3 | 6.37 Million CAD | -2.85% |
| 2012 Q1 | 6.53 Million CAD | -7.79% |
| 2011 FY | 6.56 Million CAD | -79.53% |
| 2011 Q4 | 7.08 Million CAD | -6.96% |
| 2011 Q3 | 7.61 Million CAD | -76.25% |
| 2011 Q2 | 32.06 Million CAD | 4.33% |
| 2011 Q1 | 30.73 Million CAD | -1.93% |
| 2010 Q1 | 30.1 Million CAD | 2.39% |
| 2010 Q2 | 30.92 Million CAD | 2.75% |
| 2010 Q3 | 32.2 Million CAD | 4.13% |
| 2010 Q4 | 31.34 Million CAD | -2.7% |
| 2010 FY | 32.06 Million CAD | 3.68% |
| 2009 Q1 | 33.56 Million CAD | 3.33% |
| 2009 Q3 | 29.94 Million CAD | 2.93% |
| 2009 Q2 | 29.09 Million CAD | -13.31% |
| 2009 Q4 | 29.39 Million CAD | -1.83% |
| 2009 FY | 30.92 Million CAD | 6.3% |
| 2008 Q4 | 32.48 Million CAD | -20.38% |
| 2008 Q3 | 40.79 Million CAD | -1.36% |
| 2008 Q2 | 41.36 Million CAD | -5.37% |
| 2008 Q1 | 43.7 Million CAD | -3.92% |
| 2008 FY | 29.09 Million CAD | -29.65% |
| 2007 Q3 | 25.4 Million CAD | -0.29% |
| 2007 Q1 | 25.41 Million CAD | 13.85% |
| 2007 FY | 41.36 Million CAD | 62.33% |
| 2007 Q4 | 45.49 Million CAD | 79.07% |
| 2007 Q2 | 25.47 Million CAD | 0.27% |
| 2006 Q1 | 2 Million CAD | 5.68% |
| 2006 Q4 | 22.31 Million CAD | 10.68% |
| 2006 Q2 | 1.64 Million CAD | -17.95% |
| 2006 FY | 25.47 Million CAD | 1449.52% |
| 2006 Q3 | 20.16 Million CAD | 1126.38% |
| 2005 FY | 1.64 Million CAD | -39.83% |
| 2005 Q3 | 2.14 Million CAD | -21.33% |
| 2005 Q1 | 2.57 Million CAD | 56.17% |
| 2005 Q2 | 2.73 Million CAD | 6.05% |
| 2005 Q4 | 1.89 Million CAD | -11.8% |
| 2004 Q3 | 1.29 Million CAD | 58.14% |
| 2004 Q2 | 817.57 Thousand CAD | 12.37% |
| 2004 FY | 2.73 Million CAD | 234.25% |
| 2004 Q1 | 727.55 Thousand CAD | 50.98% |
| 2004 Q4 | 1.65 Million CAD | 27.62% |
| 2003 Q2 | 353.9 Thousand CAD | -28.86% |
| 2003 Q1 | 497.47 Thousand CAD | 100.47% |
| 2003 FY | 817.57 Thousand CAD | 131.01% |
| 2003 Q3 | 376.17 Thousand CAD | 6.29% |
| 2003 Q4 | 481.87 Thousand CAD | 28.1% |
| 2002 FY | 353.9 Thousand CAD | -9.18% |
| 2002 Q4 | 248.14 Thousand CAD | -16.19% |
| 2002 Q3 | 296.08 Thousand CAD | 0.0% |
| 2001 FY | 389.66 Thousand CAD | -31.65% |
| 2000 FY | 570.07 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | 5.38 Million CAD | -51.727% |
| CanadaBis Capital Inc. | 15.61 Million CAD | 47.736% |
| Decibel Cannabis Company Inc. | 96.79 Million CAD | 91.566% |
| Delivra Health Brands Inc. | 4.85 Million CAD | -68.032% |
| Entourage Health Corp. | 178.68 Million CAD | 95.432% |
| Lifeist Wellness Inc. | 9.94 Million CAD | 17.883% |
| Cannara Biotech Inc. | 61.77 Million CAD | 86.787% |
| PharmaCielo Ltd. | 23.96 Million CAD | 65.944% |
| Rubicon Organics Inc. | 16.99 Million CAD | 51.973% |
| BioSyent Inc. | 6.76 Million CAD | -20.591% |
| Voyageur Pharmaceuticals Ltd. | 727.87 Thousand CAD | -1021.481% |